Miller Richard A MD's Form 4 filing
Corvus Pharmaceuticals, Inc. (CRVS) · filed Jun 6, 2022
- Accession no.
- 0001567619-22-012396
- Filed
- Jun 6, 2022
- Trade date
- Jun 2-6, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $5.80K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Miller Richard A MDCIK 0001031847 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 2, 2022 | Common Stock | PPurchaseAcquired | +4,830 | $0.98 | +$4,733.4 | 1,338,345 | Indirect | |
| Jun 2, 2022 | Common Stock | PPurchaseAcquired | +170 | $0.97 | +$164.9 | 1,338,515 | Indirect | |
| Jun 6, 2022 | Common Stock | PPurchaseAcquired | +890 | $1.01 | +$898.9 | 1,339,405 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.